Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroto Inaba

Showing results (131-140 of 214) with videos related to

Pageof 22
Sort By:
Journal for Immunotherapy of Cancer|March 22, 2019
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemiaRosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemiaHiroto Inaba, Jeffrey E Rubnitz, Elaine Coustan-Smith, et al.
Journal of Cancer Survivorship : Research and Practice|March 26, 2026
Association of neuropathy, sarcopenia and physical function in acute lymphoblastic leukemia survivors with chemotherapy aloneMartin Kaj Fridh, Mengqi Xing, Sedigheh Mirzaei, et al.
JAMA Network Open|May 16, 2024
Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid LeukemiaJatinder K Lamba, Richard Marrero, Huiyun Wu, et al.
Blood|September 24, 2024
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studiesKatelyn Purvis, Yinmei Zhou, Seth E Karol, et al.
Nature Communications|May 18, 2019
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AMLChristina D Drenberg, Anang Shelat, Jinjun Dang, et al.
Cancer|February 7, 2014
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemiaSima Jeha, Elaine Coustan-Smith, Deqing Pei, et al.
Clinical Pharmacology and Therapeutics|December 17, 2024
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic EthnicityMaud Maillard, Jenny Q Nguyen, Wenjian Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid LeukemiaRichard J Marrero, Huiyun Wu, Xueyuan Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2019
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor MalignanciesHiroto Inaba, John C Panetta, Stanley B Pounds, et al.
Pageof 22

Showing results (131-140 of 214) with videos related to

Sort By:
Pageof 22
Journal for Immunotherapy of Cancer|March 22, 2019
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemiaRosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemiaHiroto Inaba, Jeffrey E Rubnitz, Elaine Coustan-Smith, et al.
Journal of Cancer Survivorship : Research and Practice|March 26, 2026
Association of neuropathy, sarcopenia and physical function in acute lymphoblastic leukemia survivors with chemotherapy aloneMartin Kaj Fridh, Mengqi Xing, Sedigheh Mirzaei, et al.
JAMA Network Open|May 16, 2024
Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid LeukemiaJatinder K Lamba, Richard Marrero, Huiyun Wu, et al.
Blood|September 24, 2024
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studiesKatelyn Purvis, Yinmei Zhou, Seth E Karol, et al.
Nature Communications|May 18, 2019
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AMLChristina D Drenberg, Anang Shelat, Jinjun Dang, et al.
Cancer|February 7, 2014
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemiaSima Jeha, Elaine Coustan-Smith, Deqing Pei, et al.
Clinical Pharmacology and Therapeutics|December 17, 2024
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic EthnicityMaud Maillard, Jenny Q Nguyen, Wenjian Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid LeukemiaRichard J Marrero, Huiyun Wu, Xueyuan Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2019
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor MalignanciesHiroto Inaba, John C Panetta, Stanley B Pounds, et al.
Pageof 22